Table 2. Blood count and biochemical markers at baseline and 5–7 days after hospital admission by treatment’ group.

	SoC (n = 172)	CCS (n = 65)	TCZ (n = 50)	TCZ + CCS (n = 125)	P-value^	Total (n = 412)
Blood count and biochemical markers at baseline
White blood cells, n/μl, median [IQR]	5,515	5,830	4,820	5,850	0.4	5,600
	[4,142–7,500]	[4,120–8,900]	[3,690–7,320]	[4,200–8,280]		[4,090–7,715]
Missing, n (%)	4 (2.3%)	1 (1.5%)	1 (2%)	0 (0%)		7 (1.7%)
Neutrophils, n/μl, median [IQR]	3,580	3,650	3,390	4,385	0.054	3,680
	[2,304–5,370]	[2,450–6,420]	[2,390–5,410]	[2,850–6,580]		[2,450–5,480]
Missing, n (%)	5 (2.9%)	0 (0%)	1 (2%)	1 (0.8%)		7 (1.7%)
Lymphocytes, n/μl, median [IQR]	1,295	960	1,000	880	<0.001	1,070
	[895–1,730]	[730–1,680]	[640–1,390]	[650–1,280]		[740–1,585]
Missing, n (%)	4 (2.3%)	0 (0%)	1 (2%)	0 (0%)		5 (1.2%)
N/L ratioa, median [IQR]	2.8	3.5	4	4.4	<0.001	3.4
	[1.6–4.6]	[2.2–5.4]	[2–6.8]	[2.7–8.7]		[2.0–6.0]
Missing, n (%)	5 (2.9%)	0 (0%)	1 (2%)	1 (0.8%)		7 (1.7%)
Ferritin, μg/L, median [IQR]	302	246	585	634	<0.001	394
	[167–498]	[159–596]	[250–1,014]	[359–1,432]		[206–864]
Missing, n (%)	67 (38.9%)	32 (49.2%)	15 (30%)	46 (36.8%)		160 (38.8%)
LDHb, U/L, median [IQR]	214	281	286	302	<0.001	256
	[176–260]	[214–336]	[227–372]	[241–390]		[200–331]
Missing, n (%)	17 (9.9%)	5 (7.7%)	3 (6%)	11 (8.8%)		36 (8.7%)
D-dimer, μg FEU/ml [IQR]	0.90	1.04	1.10	1.56	0.11	1.09
	[0.48–1.70]	[0.55–2.74]	[0.66–1.79]	[0.90–2.37]		[0.6–2.08]
Missing, n (%)	50 (29.1%)	18 (27.7%)	6 (12%)	45 (36%)		119 (28.9%)
CRPc, mg/dl, median [IQR]	1	3	5	6	<0.001	3
	[0–4]	[1–9]	[2–10]	[2–12]		[1–8]
Missing, n (%)	12 (7%)	3 (4.6%)	3 (6%)	7 (5.6%)		25 (6.1%)
Blood count and biochemical markers at 5–7 days after hospital admission
White blood cells, n/μl, median [IQR]	5,290	9,020	4,585	8,205	<0.001	6,170
	[4,225–7,015]	[5,490–12,575]	[3,445–5,268]	[6,140–11,008]		[4,510–9,005]
Missing, n (%)	52 (30.2%)	14 (21.5%)	6 (12%)	9 (7.2%)		81 (19.7%)
Neutrophils, n/μl, median [IQR]	3,025	6,750	2,680	7,100	<0.001	4,050
	[2,308–4,042]	[3,745–9,628]	[1,818–3,780]	[4,325–9,115]		[2,620–7,275]
Missing, n (%)	60 (34.9%)	17 (26.1%)	6 (12%)	10 (8%)		93 (22.6%)
Lymphocytes, n/μl, median [IQR]	1,450	1,180	1,085	810	<0.001	1,125
	[1,010–1,880]	[820–1,950]	[652–1,730]	[520–1,240]		[710–1,730]
Missing, n (%)	59 (34.3%)	17 (26.1%)	6 (12%)	10 (8%)		92 (22.4%)
N/L ratioa, median [IQR]	2	4	2	9	<0.001	3
	[2–3]	[2–10]	[1–5]	[5–17]		[2–9]
Missing, n (%)	60 (34.9%)	17 (26.1%)	6 (12%)	10 (8%)		93 (22.6%)
Ferritin, μg/L, median [IQR]	286	327	598	673	<0.001	430
	[129–490]	[195–913]	[409–909]	[360–1,214]		[220–912]
Missing, n (%)	110 (63.9%)	44 (67.7%)	21 (42%)	47 (37.6%)		222 (53.9%)
LDHb, U/L, median [IQR]	186	232	280	297	<0.001	246
	[164–254]	[189–316]	[214–328]	[230–366]		[185–316]
Missing, n (%)	90 (52.3%)	34 (52.3%)	12 (24%)	24 (19.2%)		160 (38.8%)
D-dimer, μg FEU/ml [IQR]	0.72	1.18	1.38	1.98	<0.001	1.45
	[0.41–0.61]	[0.61–4.14]	[1.06–2.77]	[1.16–4.47]		[0.71–3.18]
Missing, n (%)	94 (54.6%)	38 (58.5%)	6 (12%)	20 (16%)		158 (38.3%)
CRPc, mg/dl, median [IQR]	2	1	2	1	0.008	1
	[0–6]	[0–3]	[1–6]	[0–3]		[0–4]
Missing, n (%)	56 (32.6%)	22 (33.8%)	5 (10%)	13 (10.4%)		96 (23.3%)

SoC: Standard of Care; CCS: corticosteroid; TCZ: tocilizumab; IQR: Interquartile Range;

^{^} Statistical test performed: chi-square test of independence; Kruskal-Wallis test; Fisher’s exact test.

^a Neutrophil to Lymphocyte ratio;

^b Lactate dehydrogenase;

^c C-Reactive Protein.